No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
SPRY241220P12500
- 1.50
- +0.25+20.00%
15min DelayClose Dec 20 16:00 ET
1.55High1.44Low
1.55Open1.25Pre Close13 Volume524 Open Interest12.50Strike Price1.93KTurnover0.00%IV1.61%PremiumDec 20, 2024Expiry Date1.32Intrinsic Value100Multiplier-2DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma7.45Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
ARS Pharmaceuticals Says Express Scripts Has Added Neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies
ARS Pharmaceuticals Announces Neffy (Epinephrine Nasal Spray) Is Available on Express Scripts Commercial National Formularies
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
ARS Pharmaceuticals Files For Approval Of Neffy In China, Japan And Australia
ARS Pharmaceuticals | 10-Q/A: Quarterly report (Amendment)
ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...